Literature DB >> 12698250

Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure.

Joseph A Carcillo1,2,3, Lesley Doughty4, Danny Kofos4, Reginald F Frye5,6, Sandra S Kaplan7, Howell Sasser8, Gilbert J Burckart5,6.   

Abstract

OBJECTIVE: Antipyrine metabolism is a "gold standard" measure of mixed cytochrome P450 (CYP) mediated drug metabolism in humans. Cytokines (e.g., interleukin-6) and nitric oxide reduce CYP 450 activity in vitro and in vivo. Because interleukin-6 and nitric oxide production increases in children with sepsis-induced multiple organ failure, we hypothesized impaired CYP 450 mediated drug metabolism in this population.
METHODS: Fifty-one consecutive children with sepsis and six critically ill children without sepsis were enrolled and given 18 mg/kg antipyrine per NG. Plasma antipyrine elimination rate, elimination half-life, and apparent oral clearance were measured and calculated. Plasma interleukin-6 and nitrite plus nitrate levels were measured and organs failing scored on days 1-3 of sepsis.
RESULTS: Children with sepsis had a twofold reduction in antipyrine clearance. Children with persistent failure of three or more organs had a fourfold reduction in antipyrine clearance. Antipyrine clearance was inversely correlated to circulating interleukin-6 and nitrite plus nitrate levels and to number of organ failures.
CONCLUSIONS: Interpretation CYP 450 mediated drug metabolism is decreased in children with sepsis, related in part to the degree of inflammation and organ failure. For drugs metabolized by CYP 450 enzymes there is an urgent need to reevaluate the use of standard drug dosage schedules in the sepsis population

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12698250     DOI: 10.1007/s00134-003-1758-3

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  22 in total

1.  Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.

Authors:  M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

Review 2.  Hepatic drug metabolism and immunostimulation.

Authors:  K W Renton
Journal:  Toxicology       Date:  2000-01-17       Impact factor: 4.221

3.  Inflammatory cytokine and nitric oxide responses in pediatric sepsis and organ failure.

Authors:  L A Doughty; S S Kaplan; J A Carcillo
Journal:  Crit Care Med       Date:  1996-07       Impact factor: 7.598

Review 4.  Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.

Authors:  J V St Peter; W M Awni
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

5.  Nitric oxide mediates hepatic cytochrome P450 dysfunction induced by endotoxin.

Authors:  C M Müller; A Scierka; R L Stiller; Y M Kim; D R Cook; J R Lancaster; C W Buffington; W D Watkins
Journal:  Anesthesiology       Date:  1996-06       Impact factor: 7.892

Review 6.  Regulation of cytochromes P450 during inflammation and infection.

Authors:  E T Morgan
Journal:  Drug Metab Rev       Date:  1997-11       Impact factor: 4.518

7.  Mortality associated with multiple organ system failure and sepsis in pediatric intensive care unit.

Authors:  J D Wilkinson; M M Pollack; N L Glass; R K Kanter; R W Katz; C M Steinhart
Journal:  J Pediatr       Date:  1987-09       Impact factor: 4.406

8.  Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.

Authors:  G Engel; U Hofmann; H Heidemann; J Cosme; M Eichelbaum
Journal:  Clin Pharmacol Ther       Date:  1996-06       Impact factor: 6.875

9.  Epidemiology of sepsis and multiple organ dysfunction syndrome in children.

Authors:  F Proulx; M Fayon; C A Farrell; J Lacroix; M Gauthier
Journal:  Chest       Date:  1996-04       Impact factor: 9.410

10.  Altered theophylline pharmacokinetics during acute respiratory viral illness.

Authors:  K C Chang; T D Bell; B A Lauer; H Chai
Journal:  Lancet       Date:  1978-05-27       Impact factor: 79.321

View more
  35 in total

Review 1.  Year in review in intensive care medicine-2003. Part 3: intensive care unit organization, scoring, quality of life, ethics, neonatal and pediatrics, and experimental.

Authors:  Edward Abraham; Peter Andrews; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Michael Pinsky; Peter Radermacher; Marco Ranieri; Christian Richard; Robert Tasker; Benoit Vallet
Journal:  Intensive Care Med       Date:  2004-06-26       Impact factor: 17.440

Review 2.  [Clinically relevant pharmacokinetic drug interactions in the intensive care unit: an overview].

Authors:  W Kämmerer
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-03-23       Impact factor: 0.840

3.  Sedation and analgesia in the PICU: many questions remain.

Authors:  Sandra Prins; Monique van Dijk; Dick Tibboel
Journal:  Intensive Care Med       Date:  2006-05-13       Impact factor: 17.440

Review 4.  Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients.

Authors:  Federico Pea; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 5.  Clinical Pharmacology Studies in Critically Ill Children.

Authors:  Nilay Thakkar; Sara Salerno; Christoph P Hornik; Daniel Gonzalez
Journal:  Pharm Res       Date:  2016-09-01       Impact factor: 4.200

6.  The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children.

Authors:  Enno D Wildschut; Annewil van Saet; Pavla Pokorna; Maurice J Ahsman; John N Van den Anker; Dick Tibboel
Journal:  Pediatr Clin North Am       Date:  2012-08-29       Impact factor: 3.278

7.  Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients.

Authors:  Géraldine Pettersen; Mohamad-Samer Mouksassi; Yves Théorêt; Line Labbé; Christophe Faure; Bao Nguyen; Catherine Litalien
Journal:  Br J Clin Pharmacol       Date:  2008-10-23       Impact factor: 4.335

8.  Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.

Authors:  Alison E Aitken; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2007-06-18       Impact factor: 3.922

9.  Insufficient serum caspofungin levels in a paediatric patient on ECMO.

Authors:  Birgit C P Koch; Enno D Wildschut; Anna L de Goede; Matthijs de Hoog; Roger J M Brüggemann
Journal:  Med Mycol Case Rep       Date:  2012-12-26

10.  Roles of nitric oxide in inflammatory downregulation of human cytochromes P450.

Authors:  Alison E Aitken; Choon-Myung Lee; Edward T Morgan
Journal:  Free Radic Biol Med       Date:  2007-12-23       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.